Biocartis inks breast cancer R&D deal
Belgian diagnostics company Biocartis Group NV and Singpore’s A*STAR ETPL have kicked off development of a multimodal breast cancer assay designed to guide therapy selection in personalised medicine.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
Entries by Thomas Gabrielczyk
4SC AG raises €41m
Small molecule cancer drug developer 4SC AG (Planegg-Martinsried, Germany) has completed a capital increase fueling development of its clinical programmes for resminostat, 4SC-202 and 4SC-208
Success for individualised cancer vaccine
German biotech company Biontech AG has published positive clinical results for its individualised cancer vaccine Ivac mutanome in patients with late-stage melanoma.
Seventure debuts in Japan with microbiome investment
Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventure’s Health for Life Capital investment vehicle.
Noxxon/MSD start testing of immunoncologic combo
Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.
Allergies: Public Enemy Number One
The concept has been around for more than a century, but recent advances in the field are causing numerous experts to say it’s widely underused. The goal of allergen immunotherapy (AIT) is to induce a specific immune tolerance by confronting patients with increasing levels of allergens. AIT developers are now working on improving efficacy and safety, while at the same time trying to speed up the still lengthy process of desensitisation. Peanuts in particular are in the crosshairs, as they cause one of the most life-threatening common allergies in humans.
Exscientia inks €37m contract with GSK
British pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)’s artificial intelligence (AI)-driven drug discovery platform.
Breaking therapy resistance of follicular lymphoma
Swiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy.
AML: Cellectis testing allogenic CAR-T cell therapy
Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.
Diabetes: J&J and Seventure Partners launch investment
European venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, the company’s app analyses the individual microbiome to predict blood sugar responses to thousands of different foods.